Health Topics — Immune & Antimicrobial
Recurring Infections and the Search for Something That Works Differently
For the person on their third antibiotic course this year — what the research on CBG, antimicrobial resistance, and the immune system has examined.
There is a particular frustration in recurring infections. Not just the illness itself — the skin infection that clears and comes back, the sinus infection that responds to antibiotics and returns, the UTI that you have treated more times than you can count — but the growing sense that you are managing a cycle rather than addressing something underneath it.
The search for something that works differently is reasonable. And there is research worth knowing about — with honest limits clearly stated.
Recurring infections often have more than one cause. For skin infections, the bacteria involved — frequently Staphylococcus aureus, including antibiotic-resistant forms — can colonize skin and return after treatment because the colonization itself was never fully cleared. For respiratory infections, structural factors, immune function, and environmental exposure all contribute. For urinary tract infections, anatomy, microbiome disruption, and hormonal factors create recurring vulnerability. Understanding which type of recurring infection you're dealing with changes what the relevant research is.
What most recurring infection cycles have in common is antibiotic exposure — often repeated antibiotic exposure. And repeated antibiotic exposure has its own consequences: disruption of the microbiome, which is itself part of the immune system's first-line defense, and selective pressure that favors resistant bacterial strains. The cycle is real and documented: infection, antibiotic, cleared, return, antibiotic again — with each cycle potentially making the next more difficult.
What the CBG antimicrobial research has found
The most significant CBG antimicrobial finding is against MRSA — methicillin-resistant Staphylococcus aureus, the antibiotic-resistant bacterium responsible for many difficult-to-treat skin infections and hospital-acquired infections. The Farha et al. (2020) study found CBG effective against MRSA both in laboratory cell culture and in a mouse model — where CBG reduced MRSA bacterial loads comparably to vancomycin, a last-resort antibiotic used for serious resistant infections. The biofilm-disrupting activity was also documented — CBG affected the structured bacterial communities that are particularly resistant to antibiotics.
The mechanism involves disruption of bacterial membrane integrity and interference with the bacterial electron transport chain — processes that bacteria use to maintain their structure and pump antibiotics out of the cell. Research has also found that CBG can enhance the activity of existing antibiotics against MRSA, potentially acting as an antibiotic adjuvant — something that restores effectiveness to antibiotics bacteria have learned to resist.
The mouse model finding is meaningful — it places CBG's MRSA research on a stronger footing than most cannabinoid antimicrobial work, which stays in cell culture. But the gap between a mouse model and a clinical antimicrobial remains large. Many compounds that perform well in animal models fail to become antibiotics for reasons of bioavailability, toxicity, and human pharmacology. No human trial of CBG as an antimicrobial has been conducted. What the research establishes is a mechanism, an animal model signal, and a genuine direction for further research — not a clinical application.
CBG also has early research on activity against Candida — the fungal species responsible for yeast infections — in laboratory biofilm models. This research is thinner than the antibacterial thread and requires the same distance from in vitro finding to clinical relevance.
What this means in practice
We can't tell you that a CBG preparation will prevent or resolve recurring infections. The research does not support that claim and we do not make it. What the research provides is a picture of CBG's biological interactions with the bacteria most commonly involved in recurring infections — interactions that are real, documented, and scientifically interesting without being clinically established.
The most honest framing for the person in a recurring infection cycle: CBG's antimicrobial research is in a domain where the science is genuinely interesting, where the mechanisms are relevant, and where the gap between the laboratory and clinical application is significant and should be stated directly. This is not a complement to antibiotic treatment — it is a separate area of early research that may eventually produce clinical applications we don't yet have.
On infections and clinical care
Recurring bacterial or fungal infections warrant clinical assessment. In some cases they reflect structural factors, immune function issues, or resistant organisms that require specific diagnosis and targeted treatment. Antibiotic resistance is a serious concern — any infection that fails to respond to standard treatment should be assessed by a clinician.
Nothing in this article or this archive constitutes guidance on treating bacterial or fungal infections.
Future articles in this pillar examine the MRSA research in detail, the immune system's CB2 receptor biology, and the oral microbiome research where CBG's antibacterial properties have specific relevance. The research section is the place to start for the fuller picture.
Recurring infections and the antibiotic cycle are a documented problem — both for individual health and for the broader challenge of antimicrobial resistance. CBG's antimicrobial research is real, specific, and has moved beyond the laboratory dish into a mouse model — which is meaningful, and which still leaves a significant distance from clinical application. We have tried to present all of that clearly, because the person in this cycle deserves honest information about what the research has and hasn't established.
These statements have not been evaluated by the Food and Drug Administration. J.P. Hemp Company products are not intended to diagnose, treat, cure, or prevent any disease.